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Abstract
In this issue of Critical Care, Megarbane and colleagues present a
case report of methadone-induced respiratory depression and
conduct a toxicokinetic/toxicodynamic evaluation. An opioid-
dependent patient receiving methadone maintenance treatment
(daily dose 70 mg) was found unconscious after ingesting 240 mg
methadone and 2 mg flunitrazepam. Significant improvement in
consciousness was achieved after an intravenous bolus of 0.3 mg
naloxone followed by a continuous infusion of naloxone at
0.3 mg/hour. In patients receiving methadone maintenance
treatment, an occasional intake of two to four times the usual daily
dose of methadone is not an exceptional occurrence. However,
few such patients experience episodes of life-threatening
respiratory depression. Here, we discuss whether recent
pharmacogenetic data could help us to understand interindividual
variability in sensitivity to respiratory depression and, ultimately, to
predict which patients are most likely to be affected.
The case report by Megarbane and colleagues [1] reminds us
that full tolerance to the opioid effects of methadone may
never fully develop, even after long-term methadone mainten-
ance treatment. Thus, even in tolerant patients, intake of a
dose that is too high, up-titration of methadone dosage that is
too rapid, or introduction of strong inhibitor(s) of methadone
metabolism could cause life-threatening respiratory depres-
sion [2]. Interestingly, the maximal observed (R,S)-methadone
plasma concentration (1204 ng/ml) in this case report is not,
as stated, three times higher than peak levels in patients
treated with a daily dosage in excess of 80 mg (mean dose ±
standard deviation: 134 ± 82 mg/day, n = 209) [3]. Actually,
it is only 68% higher than the mean peak (R,S)-methadone
concentration (715 ± 395 ng/ml) and half the highest
measured peak (R,S)-methadone concentration [3].
There are many factors that can contribute to the
interindividual variability in sensitivity to respiratory depression
following intake of a high dose of methadone in tolerant
patients. Simultaneous intakes of other central respiratory
depressing agents such as benzodiazepines and alcohol are
important risk factors [2]. The case report gives no indication
as to whether alcohol was also used by the patient, although
screening of blood for benzodiazepines, opiates, buprenor-
phine, cocaine and tetrahydrocannabinol was negative except
for methadone [1]. The patient declared that the only other
substance taken with methadone was 2 mg flunitrazepam. If
this was true, then it is unlikely that this small quantity of
flunitrazepam, in a patient who already had a history of
occasional use of this benzodiazepine, could be a major
factor contributing to the episode of respiratory depression.
In recent years interest in pharmacogenetic studies has
grown; these studies aim to achieve a better understanding
of interindividual variability in the response to treatment.
Some tentative explanations for this variability might come
from both pharmacokinetic and pharmacodynamic lines of
inquiry. At the pharmacokinetic level, the first factor to
consider is the enzymes that are involved in the metabolism of
methadone, which is mainly mediated by cytochrome P450
(CYP)2B6 and CYP3A4, with a minor contribution from
CYP2D6 [4]. CYP2B6 exhibits stereoselectivity toward the
(S)-enantiomer of methadone [4], which is almost inactive as
a µ-opioid receptor agonist [2]. In contrast, CYP3A4 is not
stereoselective [4] and CYP2D6 could be stereoselective
toward the active form of methadone, namely (R)-methadone
[5,6]. It has been demonstrated that activity of these enzymes
can be impaired as a result of genetic [4] and environmental
(for example, inhibition of their activity by comedication and/or
diet) factors. However, low metabolic activity cannot be
proposed as an explanation for the episode of respiratory
depression in the case described by Megarbane and
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colleagues [1] because a short half-life for both enantiomers
of methadone was measured, suggesting rapid metabolism.
A second factor that possibly contributes to interindividual
sensitivity to methadone is the permeability glycoprotein
(PGP), which is a transmembrane efflux transporter expressed
in various human tissues, including intestine, liver and blood-
brain barrier [7]. Genetic polymorphisms have been
described for PGP that can contribute to differences in blood
concentrations of methadone [4]. More importantly, a major
role for PGP in limiting access of xenobiotics to the brain has
been demonstrated in vivo in PGP-deficient mice, with little
influence on blood concentrations [8]. Interindividual
variability in PGP activity is therefore a strong candidate in
genetically mediated sensitivity to methadone-induced
respiratory depression. Another factor that may be involved in
methadone pharmacokinetics is the strong blood binding of
methadone to plasma proteins, in particular to α-acid
glycoprotein, which could significantly alter methadone
pharmacokinetics [2]. However, despite the presence of
genetic polymorphisms in α1-acid glycoprotein and differen-
tial binding of methadone to its variants [9], it is presently not
possible to determine whether and to what extent this could
influence sensitivity to respiratory depression.
At the pharmacodynamic level the most interesting factors
are genetic polymorphisms described for the µ-opioid
receptor, in particular the 118A>G single nucleotide
polymorphism at exon 1 of the OPRM1 gene. In vitro, the
variant protein has been demonstrated to exhibit three times
greater binding affinity for the endopeptide β-endorphin,
whereas binding to substances such as morphine, fentanyl,
methadone and naloxone were unaffected [10]. However, in
vivo, (R)-methadone had 1.74 times lower miotic potency
(P < 0.001) in carriers of the variant 118G allele as
compared with noncarriers [11]. In addition, alfentanil
concentrations that were two to four times greater were
needed in homozygous carriers of the 118G allele as
compared with wild-type subjects to produce the same
degree of analgesia, and 10 to 12 times higher alfentanyl
concentrations were needed to produce the same degree of
respiratory depression [12]. This suggests an important
difference in sensitivity to respiratory depression depending
on whether the 118A>G single nucleotide polymorphism is
present. It should be noted that although genetic
polymorphism in the µ-opioid receptor appears an interesting
candidate for contributing to interindividual variability in
sensitivity to opioid agonist induced respiratory depression,
caution should be exercised when extrapolating the data from
these single-dose studies to cases of overdose in tolerant
patients. However, the 118A>G polymorphism in the human
µ-opioid receptor gene also affects response to treatment
after multiple doses as well, because cancer patients
homozygous for the 118G allele need higher morphine doses
to achieve pain control [13].
In summary, studies are needed to elucidate the inter-
individual variability in sensitivity to respiratory depression
among opioid-dependant patients receiving methadone
maintenance treatment. In this regard, genetic polymorphism
in CYP isozymes, PGP and the µ-opioid receptor would be
interesting factors to consider in future investigations.
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